Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521344 | 0.80 | CHRM1 (0.39) | — | |
| SCHEMBL6509835 | 0.76 | GAA (0.31) | — | |
| SCHEMBL14836211 | 0.76 | GLRA1 (0.33) | TDP1 | |
| SCHEMBL7746730 | 0.75 | — | — | |
| SCHEMBL29155241 | 0.71 | CTSD (0.31) | — | |
| SCHEMBL18322817 | 0.71 | — | — | |
| SCHEMBL8605865 | 0.71 | — | — | |
| SCHEMBL29155250 | 0.70 | TDP1 (0.36) | TDP1 | |
| SCHEMBL7747137 | 0.69 | HDAC6 (0.36) | — | |
| SCHEMBL582879 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172962-B2 | Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-01-08 | — | — | US | claimed |
| US-10092662-B2 | Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2018-10-09 | — | — | US | claimed |
| US-20180207296-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-07-26 | — | — | US | claimed |
| EP-3338816-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING IMPLANT LOOSENING AND OSTEOLYSIS | Board Of Regents Of The University Of Nebraska (US) | 2018-06-27 | — | — | EP | claimed |
| US-20210214389-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA, LLC | 2021-07-15 | — | — | US | disclosed |
| EP-3843749-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | Osteoanalgesia, LLC (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020047231-A9 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020047231-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | OSTEOANALGESIA LLC (US) | 2020-03-05 | — | — | WO | disclosed |
| EP-2210616-A1 | Multifunctional stealth nanoparticles for biomedical use | Centre National de la Recherche Scientifique (FR) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214389-A1 | DIASTEREOMERIC CONJUGATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | NR3C1, GCG, NR3C2 | TDP1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.